Active Ingredient History
Aripiprazole is the first next-generation atypical antipsychotic. The unique actions of aripiprazole in humans are likely a combination of "functionally selective" activation of D(2) (and possibly D(3))-dopamine receptors and serotonin 5-HT(1A) receptors, coupled with inhibition of 5-HT(2A) receptors. Aripiprazole was approved by FDA (Abilify trade name) for the treatment of schizophrenia; manic and mixed episodes associated with bipolar I disorder; major depressive disorder; irritability associated with autistic disorder; Tourette’s disorder and agitation associated with schizophrenia or bipolar mania. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Autistic Disorder (approved 2002)
Depressive Disorder, Major (approved 2002)
Tourette Syndrome (approved 2002)
Acute Pain (Phase 2)
Aggression (Phase 4)
Alcoholism (Phase 4)
Alzheimer Disease (Phase 4)
Amphetamine-Related Disorders (Phase 1)
Analgesia (Phase 4)
Anesthesia (Phase 4)
Anorexia Nervosa (Phase 3)
Antipsychotic Agents (Phase 4)
Anxiety Disorders (Phase 4)
Aripiprazole (Phase 4)
Asperger Syndrome (Phase 2)
Asthma (Phase 4)
Autism Spectrum Disorder (Phase 4)
Behavioral Symptoms (Phase 3)
Bipolar and Related Disorders (Phase 4)
Body Weight (Phase 4)
Body Weight Changes (Phase 3)
Cardiovascular Diseases (Phase 4)
Central Nervous System Diseases (Phase 1)
Central Nervous System Stimulants (Phase 3)
Child Development Disorders, Pervasive (Phase 4)
Cocaine-Related Disorders (Phase 2)
Conduct Disorder (Phase 4)
Cytochrome P-450 CYP2D6 (Phase 4)
Cytochrome P-450 CYP3A (Phase 4)
Dementia (Phase 4)
Depression (Phase 4)
Depression, Postpartum (Phase 3)
Depressive Disorder, Major (Phase 4)
Depressive Disorder, Treatment-Resistant (Phase 4)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Diagnosis (Phase 3)
Drugs, Investigational (Phase 4)
Drug Therapy (Phase 2/Phase 3)
Dyskinesia, Drug-Induced (Phase 4)
Dyslipidemias (Phase 4)
Dysthymic Disorder (Phase 4)
Feeding and Eating Disorders (Phase 4)
Fragile X Syndrome (Phase 2)
Growth and Development (Phase 3)
Healthy Volunteers (Phase 1)
HIV Infections (Phase 2)
Hyperlipidemias (Phase 4)
Hyperprolactinemia (Phase 4)
Hysterotomy (Phase 4)
Immunoassay (Phase 1)
Insulin Resistance (Phase 4)
Low Back Pain (Phase 2)
Mammaplasty (Phase 2)
Mania (Phase 4)
Medication Adherence (Phase 4)
Mental Disorders (Phase 2)
Mental Health (Phase 4)
Metabolic Diseases (Phase 4)
Metabolic Syndrome (Phase 4)
Methamphetamine (Phase 4)
Mood Disorders (Phase 4)
Nervous System Diseases (Phase 2)
Obsessive-Compulsive Disorder (Phase 2)
Opioid-Related Disorders (Phase 1)
Overweight (Phase 4)
Panic Disorder (Phase 4)
Parkinson Disease (Phase 4)
Pharmacokinetics (Phase 4)
Phobia, Social (Phase 4)
Psychophysiologic Disorders (Phase 3)
Risk Factors (Phase 4)
Sexual Dysfunction, Physiological (Phase 4)
Stress Disorders, Post-Traumatic (Phase 3)
Substance Abuse, Oral (Phase 3)
Substance-Related Disorders (Phase 4)
Tic Disorders (Phase 4)
Tourette Syndrome (Phase 4)
Weight Gain (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
